NF-kappa-B decoy oligonucleotide - AnGes MG

Drug Profile

NF-kappa-B decoy oligonucleotide - AnGes MG

Alternative Names: AMG0101; AMG0102; AMG0103; AMS-001; MP 40; MP 41; MP 42; NDON; NF-kappa-B decoy oligo; NF-KB decoy oligo; S-414114; SI-3104

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator AnGes MG; Osaka University
  • Developer Aichi Gakuin University; AnGes MG; Hosokawa Micron Corporation; Medikit; Morishita Jintan; Nippon Zoki; Osaka University
  • Class Anti-inflammatories; Antirheumatics; Oligonucleotides
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Clinical Phase Unknown Vascular restenosis
  • Preclinical Inflammatory bowel diseases; Intervertebral disc degeneration; Musculoskeletal disorders; Pain; Respiratory tract disorders
  • Discontinued Periodontal disorders; Psoriasis; Spondylosis

Most Recent Events

  • 28 Jul 2016 Efficacy and safety data from a phase III trial in Atopic dermatitis released by AnGes
  • 05 Feb 2016 AnGes MG completes enrolment in its phase III trial for Atopic Dermatitis in Japan
  • 05 May 2015 AnGes MG plans a phase I/II trial for Intervertebral disc degeneration in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top